The capsule is an immuno-suppressant used for preventing organ rejection in certain patients following liver, kidney, or heart transplant.
Pharmaceutical firm Strides Arcolab has received the regulatory approval to market Tacrolimus capsules in the US market.
The capsule is an immuno-suppressant used for preventing organ rejection in certain patients following liver, kidney, or heart transplant.
The company has been allowed by United States Food and Drug Administration (USFDA) to sell Tacrolimus capsules in the strengths of 0.5 mg, 1 mg and 5 mg, Strides Arcolab said in a BSE filing.
The US market for generic Tacrolimus is approximately USD 676 million, the company said, citing IMS data.
"The product will be manufactured at the company's oral dosage facility at Bangalore and marketed directly by Strides in the US market," the company said in a statement.
Strides Arcolab's shares were trading 0.62 percent down at Rs 670 apiece during afternoon trade on the BSE.
Strides Arcolab stock price
On July 23, 2014, Strides Arcolab closed at Rs 671.50, down Rs 2.7, or 0.4 percent. The 52-week high of the share was Rs 1050.00 and the 52-week low was Rs 343.80.
The company's trailing 12-month (TTM) EPS was at Rs 584.46 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 1.15. The latest book value of the company is Rs 820.12 per share. At current value, the price-to-book value of the company is 0.82.
Anda sedang membaca artikel tentang
Strides Arcolab gets USFDA approval to sell transplant drug
Dengan url
https://gayafashionshow.blogspot.com/2014/07/strides-arcolab-gets-usfda-approval-to.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Strides Arcolab gets USFDA approval to sell transplant drug
namun jangan lupa untuk meletakkan link
Strides Arcolab gets USFDA approval to sell transplant drug
sebagai sumbernya
0 komentar:
Posting Komentar